Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis
Open Access
- 2 November 2015
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (2) , 277-282
Abstract
Risk factors for non-Aspergillus mold infection (NAMI) and the impact on transplant outcome are poorly assessed in the current era of antifungal agents. Outcomes of 124 patients receiving allogeneic hematopoietic cell transplantation (HCT) diagnosed with either mucormycosis (n=72) or fusariosis (n=52) between days 0 and 365 after HCT are described and compared with a control cohort (n=11 856). Patients with NAMI had more advanced disease (mucormycois: 25%, fusariosis: 23% and controls: 18%; P=0.004) and were more likely to have a Karnofsky performance status (KPS) P=0.048). The 1-year survival after HCT was 22% (15–29%) for cases and was significantly inferior compared with controls (65% (64–65%); PPAspergillus infection and older age. For fusariosis, increased risks including receipt of cord blood, prior CMV infection and transplant before May 2002. In conclusion, NAMI occurs infrequently, is associated with high mortality and appears with similar frequency in the current antifungal era.Keywords
This publication has 24 references indexed in Scilit:
- Breakthrough invasive mould infections in patients treated with caspofunginJournal of Infection, 2012
- Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapyBone Marrow Transplantation, 2007
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving VoriconazoleClinical Infectious Diseases, 2004
- Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole ProphylaxisClinical Infectious Diseases, 2004
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioningBlood, 2003
- Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2002
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974